<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the present study we carried out allogeneic bone marrow transplantation (BMT) in 14 <z:hpo ids='HP_0001909'>leukemia</z:hpo> children with high risk prognostic factors </plain></SENT>
<SENT sid="1" pm="."><plain>Six patients with <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ANLL), four with <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL), two with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), and two with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Among these patients, six with ANLL, two with ALL, one with <z:mp ids='MP_0005481'>CML</z:mp> and one with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were alive in complete remission 8 to 58 months post-BMT </plain></SENT>
<SENT sid="3" pm="."><plain>Four patients died of relapse (one with ALL, and one with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (one with ALL and one with <z:mp ids='MP_0005481'>CML</z:mp>) </plain></SENT>
<SENT sid="4" pm="."><plain>In six patients recombinant granulocyte colony stimulating factor (rG-CSF) was used to shorten the period of <z:hpo ids='HP_0001913'>granulocytopenia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The mean time of recovery to granulocyte count of 500/mm3 was 13.2 days in the rG-CSF+ group, being 15.9 days faster than that in the rG-CSF- group </plain></SENT>
<SENT sid="6" pm="."><plain>In light of these results, allogeneic BMT is shown to be a choice of treatment for <z:hpo ids='HP_0001909'>leukemia</z:hpo> children with high risk prognostic factors and rG-CSF may be an effective reagent to prevent infectious episodes in BMT </plain></SENT>
</text></document>